Professional Insights: Lyme Disease Diagnostic Market Research 2026 Recent Lyme Disease Diagnostic Market research highlights a critical shift in sample types. While blood/serum remains the dominant medium (over 62% share), there is a significant 7.2% CAGR growth in urine-based antigen testing and cerebrospinal fluid (CSF) analysis for neurological Lyme cases. Research indicates that the use of synthetic peptides—instead of whole proteins—in new assays has increased specificity to nearly 100%, virtually eliminating the cross-reactivity issues that previously plagued the industry. https://www.marketresearchfuture.com/reports/lyme-disease-diagnostic-market-42027 Insights from 2025-2026 also point toward a "One-Step" diagnostic revolution. New hybrid ELISA designs allow for the simultaneous binding of two distinct antigens, effectively merging the traditional screening and confirmatory steps into a single 20-minute test. This development is particularly vital for emergency departments, where the ability to start a 10-day course of doxycycline immediately can prevent the long-term heart and joint complications associated with disseminated Lyme disease. FAQ: Question: Which diagnostic technology currently holds the largest revenue share? Answer: Serological (antibody-based) tests like ELISA and Western Blot still hold the majority of the market revenue due to their established infrastructure.